EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Cytisinicline for Smoking Cessation

Nancy A Rigotti, Neal L Benowitz, Judith Prochaska, Scott Leischow, Mitchell Nides, Brent Blumenstein, Anthony Clarke, Daniel Cain, Cindy Jacobs

JAMA · 11.07.2023 · 330 (2) · 152

DOI: 10.1001/jama.2023.10042 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA, erschienen am 11.07.2023. Verfasst von Nancy A Rigotti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Department of Medicine, Massachusetts General Hosp…. Hauptthemen laut MEDLINE: Smoking Cessation, Tobacco Use Disorder, Smoking Cessation Agents, Quinolizidine Alkaloids. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Cytisinicline (cytisine) is a plant-based alkaloid that, like varenicline, binds selectively to α4β2 nicotinic acetylcholine receptors, which mediate nicotine dependence. Although not licensed in the US, cytisinicline is used in some European countries to aid smoking cessation, but its traditional dosing regimen and treatment duration may not be optimal.

Objective

To evaluate the efficacy and tolerability of cytisinicline for smoking cessation when administered in a novel pharmacokinetically based dosing regimen for 6 or 12 weeks vs placebo. Design, Setting, and Participants A 3-group, double-blind, placebo-controlled, randomized trial (ORCA-2) compared 2 durations of cytisinicline treatment (6 or 12 weeks) vs placebo, with follow-up to 24 weeks, among 810 adults who smoked cigarettes daily and wanted to quit. It was conducted at 17 US sites from October 2020 to December 2021.

Interventions

Participants were randomized (1:1:1) to cytisinicline, 3 mg, 3 times daily for 12 weeks (n = 270); cytisinicline, 3 mg, 3 times daily for 6 weeks then placebo 3 times daily for 6 weeks (n = 269); or placebo 3 times daily for 12 weeks (n = 271). All participants received behavioral support. Main Outcomes and Measures Biochemically verified continuous smoking abstinence for the last 4 weeks of cytisinicline treatment vs placebo (primary) and from end of treatment to 24 weeks (secondary).

Results

Of 810 randomized participants (mean age, 52.5 years; 54.6% female; mean of 19.4 cigarettes smoked daily), 618 (76.3%) completed the trial. For the 6-week course of cytisinicline vs placebo, continuous abstinence rates were 25.3% vs 4.4% during weeks 3 to 6 (odds ratio [OR], 8.0 [95% CI, 3.9-16.3]; P < .001) and 8.9% vs 2.6% during weeks 3 to 24 (OR, 3.7 [95% CI, 1.5-10.2]; P = .002). For the 12-week course of cytisinicline vs placebo, continuous abstinence rates were 32.6% vs 7.0% for weeks 9 to 12 (OR, 6.3 [95% CI, 3.7-11.6]; P < .001) and 21.1% vs 4.8% during weeks 9 to 24 (OR, 5.3 [95% CI, 2.8-11.1]; P < .001). Nausea, abnormal dreams, and insomnia occurred in less than 10% of each group. Sixteen participants (2.9%) discontinued cytisinicline due to an adverse event. No drug-related serious adverse events occurred. Conclusions and Relevance Both 6- and 12-week cytisinicline schedules, with behavioral support, demonstrated smoking cessation efficacy and excellent tolerability, offering new nicotine dependence treatment options. Trial Registration ClinicalTrials.gov Identifier: NCT04576949

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smoking CessationTobacco Use DisorderSmoking Cessation AgentsQuinolizidine AlkaloidsCigarette SmokingHumansMiddle AgedAlkaloidsAzocinesDuration of TherapyQuinolizinesDouble-Blind MethodTreatment OutcomeMaleFemaleNicotineReceptors, Nicotinic

Substanzen

AlkaloidsAzocinescytisineQuinolizinesSmoking Cessation AgentsQuinolizidine AlkaloidsNicotinenicotinic receptor alpha4beta2Receptors, Nicotinic

Autor:innen und Institutionen

  • Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Research Program in Clinical Pharmacology, Division of Cardiology, Department of Medicine, University of California San Francisco.
  • Department of Medicine and Stanford Prevention and Research Center, Stanford University, Stanford, California.
  • College of Health Solutions, Arizona State University, Phoenix.
  • Los Angeles Clinical Trials, Burbank, California.
  • Trial Architecture Consulting, Chevy Chase, Maryland.

Zitieren

APA

Rigotti, N. A., Benowitz, N. L., Prochaska, J., Leischow, S., Nides, M., Blumenstein, B., Clarke, A., Cain, D., & Jacobs, C. (2023). Cytisinicline for Smoking Cessation. JAMA, 330(2), 152. https://doi.org/10.1001/jama.2023.10042

Vancouver

Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B, et al. Cytisinicline for Smoking Cessation. JAMA. 2023;330(2):152. doi:10.1001/jama.2023.10042

BibTeX
@article{Rigotti2023,
  author = {Rigotti, Nancy A and Benowitz, Neal L and Prochaska, Judith and Leischow, Scott and Nides, Mitchell and Blumenstein, Brent and Clarke, Anthony and Cain, Daniel and Jacobs, Cindy},
  title = {Cytisinicline for Smoking Cessation},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {2},
  pages = {152},
  doi = {10.1001/jama.2023.10042}
}
Kostenlos starten →